Form 4: Tenaya Therapeutics CSO Timothy Hoey Sells Shares Under 10b5-1 Trading Plan

Tenaya Therapeutics' Chief Scientific Officer, Timothy Hoey, sold 3,300 shares of common stock at an average price of $7.0003 on March 5, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 5, 2024, Timothy Hoey, the Chief Scientific Officer of Tenaya Therapeutics, Inc. (TNYA), sold 3,300 shares of the company's common stock.
• The sale was executed at a weighted average price of $7.0003 per share, with individual transactions ranging from $7.00 to $7.01.
• This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2023.
• Following the reported transaction, Hoey beneficially owns 245,346 shares, which includes 50,000 shares issuable upon vesting of restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Insider sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares over a period of time while avoiding concerns about trading on non-public information. Investors often monitor insider transactions for signals about a company's prospects, although sales under a 10b5-1 plan are generally less informative than discretionary trades.

Stakeholder Impact

• The sale of shares by a company officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates